好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comorbidities Associated With Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Among People Living With HIV
Infectious Disease
S22 - Neuroinfectious Disease: Basic Sciences (1:24 PM-1:36 PM)
003

To examine associations between comorbidities and plasma levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in people living with HIV (PLWH) on antiretroviral therapy (ART) without cognitive impairment.

NfL and GFAP are increasingly studied as biomarkers in neurologic conditions. Their use among PLWH has been proposed, but examination of levels among cognitively unimpaired PLWH on ART and associations with comorbidities are needed to optimize interpretation.

The study population included cognitively unimpaired PLWH from the ACTG HAILO study: age ≥45 years, on ART, with HIV RNA <200 copies/mL, and eGFR≥30 mL/min/1.73m2. Cognitively unimpaired status was based on composite results of four neuropsychological tests. Plasma NfL and GFAP were quantified by the Simoa assay. Multivariable linear regression models for log-transformed NfL and GFAP were fitted to examine cross-sectional relationships between biomarker levels and ASCVD risk, eGFR, neuropathy, demographics, and HIV-related variables.

Among 371 subjects, mean (SD) age was 53.2 (6.3) years, 67 (18.1%) were female, and 209 (56.3%) were non-Hispanic White. Mean (SD) BMI was 28.5 (5.8) kg/mm3, 31 (8.4%) had eGFR <60, and 207 (57.8%) had ASCVD risk ≥5%. In linear regression, age (β= 0.090, p<0.001) and self-identified White race (β=0.085, p<0.001) were positively associated with NfL. GFR (β= -0.065, p<0.001), BMI (β= -0.011, p<0.001), and CD4 nadir (β= -0.007, p=0.032) were negatively associated with NfL. Age (β= 0.107, p<0.001) was positively associated with GFAP. GFR (β= -0.084, p<0.001), BMI (β= -0.004, p=0.040), ASCVD risk (β= -0.018, p=0.024), and male sex at birth (β= -0.100, p=0.001) were negatively associated with GFAP. HIV-related factors did not show clinically impactful associations with either biomarker.

In this cross-sectional analysis of cognitively unimpaired PLWH, age, lower eGFR and BMI were associated with higher NFL and GFAP. ASCVD risk and race showed variable associations. HIV-related factors did not show clinically impactful associations.
Authors/Disclosures
Elena Beideck, MD
PRESENTER 		Dr. Beideck has nothing to disclose.
Petra Bachanova Miss Bachanova has received personal compensation for serving as an employee of Dartmouth College.
Linzy Rosen Ms. Rosen has nothing to disclose.
Hemi Park, MPH Ms. Park has nothing to disclose.
Pia Kivisakk Webb, MD, PhD Dr. Kivisakk Webb has nothing to disclose.
Felicia Chow, MD (Zuckerberg San Francisco General Hospital) Dr. Chow has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Medicolegal consulting. The institution of Dr. Chow has received research support from NIH.
Kunling Wu Ms. Wu has nothing to disclose.
Leah H. Rubin, PhD Dr. Rubin has nothing to disclose.
Katherine Tassiopoulos, DSc Dr. Tassiopoulos has nothing to disclose.
Robert W. Parker III, PharmD Dr. Parker has nothing to disclose.
Emily Hyle, MD The institution of Dr. Hyle has received research support from NIH. The institution of Dr. Hyle has received research support from MGH. Dr. Hyle has received publishing royalties from a publication relating to health care.
Shibani S. Mukerji, MD, PhD (Massachusetts General Hospital) Dr. Mukerji has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Dynamed. Dr. Mukerji has or had stock in Gilead Science.Dr. Mukerji has or had stock in Ranpack.Dr. Mukerji has or had stock in Snowflake. An immediate family member of Dr. Mukerji has or had stock in Amgen. The institution of Dr. Mukerji has received research support from NIH. The institution of Dr. Mukerji has received research support from Massachusetts General Hospital.